The initial success of Viagra undeniably transformed the pharmaceutical landscape, but investing in companies strongly reliant on off-patent versions presents a uncertain picture. While early returns were substantial, the end of patents and the rise of discounted alternatives have eroded market share. Thus, a thorough analysis of present income sou